[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NovoBliss Research Pvt Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":338},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,46,67,91,113,139,160,181,200,215,236,257,278,299,319],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100628824","to-determine-the-effect-of-phaseolean-on-glycemic-response-to-carbohydrate-rich-meal-in-healthy-adult-human-participants-100628824",false,"NCT07466667","To Determine the Effect of Phaseolean on Glycemic Response to Carbohydrate Rich Meal in Healthy Adult Human Participants","An Open-Label, Randomized, Three-Way, Three-Arm, Crossover, Balance Study to Evaluate the Effect of Phaseolean on Healthy Glycemic Response to Carbohydrate- Rich Meals in Healthy Adult Participants Using an In Vivo Method","PHEGI","Inclusion Criteria:\n\n1)Age: 18 to 45 years (both inclusive) at the time of consent Sex: male and non-pregnant\u002Fnon-lactating female. 3) Females of childbearing potential must have a negative urine pregnancy test performed on screening visits.\n\n4\\) Participants having fasting blood glucose levels less than 100 milligrams per decilitre.\n\n5\\) Participants with a Body Mass Index of 18.5 to 25 kilogram per meter square (both inclusive).\n\n6\\) Participant is in good general health as determined by the Investigator on the basis of medical history and vital signs.\n\n7\\) Participants should be willing and able to follow the study protocol to participate in the study.\n\n8\\) Participant must be able to understand and provide written informed consent to participate in the study.\n\n9\\) Participant is willing to refrain from vigorous physical exercise during the study period.\n\n10\\) Participants is willing to stay overnight as per study specification requirements.\n\nExclusion Criteria:\n\n1. Participant has any known food allergy or intolerance to any food or beverages.\n2. Participant is taking any medication in the past one week.\n3. Participants should not be taking any medications known to affect glucose tolerance (excluding oral contraceptives) - stable doses of oral contraceptives, acetylsalicylic acid, thyroxin, vitamins and mineral supplements or drugs to treat hypertension or osteoporosis are acceptable\n4. Participants should not have any known food allergy or intolerance\n5. Presence of any chronic disease or illness in the past three months or any clinically significant on-going chronic medical illness e.g. Congestive cardiac failure, Hepatitis, Hypotensive episodes, etc.\n6. Recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 24 hours prior to the study.\n7. Participation in any similar clinical trial within the past 90 days with blood loss more than 450 millilitre.\n8. An unusual diet, special diet, for whatever reason e.g. high protein diet, low sodium diet, for two weeks prior to receiving any test food and throughout the Participant's participation in the study.\n9. Participant has performed vigorous physical exercise in the morning on dosing day.\n10. Pregnant or lactating females.\n11. Self-reported Positive Human Immunodeficiency Virus test.\n12. History of Hepatitis B or C virus self-reported",true,"ALL","18 Years","45 Years",{"count":22,"type":23},12,"ESTIMATED","INTERVENTIONAL",[26],"NA","This is an Open-Label, Randomized, Three-Way, Three-Arm, Crossover, Balance Study to Evaluate the Effect of Phaseolean on Glycemic response to carbohydrate rich meals in Healthy Adult Participants Using an In Vivo Method.",[29],"Healthy",[31,32,33],"Phaseolean","Glycemic Response","Anhydrous Glucose Powder","NOT_YET_RECRUITING","2026-03-21",{"date":37,"type":38},"2026-03-25","ACTUAL",{"date":40,"type":23},"2026-03-16",{"date":42,"type":23},"2026-04-30",{"name":44,"class":45},"NovoBliss Research Pvt Ltd","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100625491","validation-of-skin-instrumentation-to-detect-ceramide-driven-lipid-replenishment---assessing-skin-glow-hydration-trans-epidermal-water-loss-skin-surface-assessment-sebum-and-least-reflection-factor-100625491","NCT07423325","Validation of Skin Instrumentation to Detect Ceramide-Driven Lipid Replenishment - Assessing Skin Glow, Hydration, Trans Epidermal Water Loss, Skin Surface Assessment, Sebum and Least-Reflection Factor.","Validation of Skin Instrumentation to Detect Ceramide-Driven Lipid Replenishment - Assessing Skin Glow, Hydration, Trans Epidermal Water Loss, Skin Surface Assessment, Sebum and Least-Reflection Factor","Inclusion Criteria:\n\n* 1\\) Age: 18 to 55 years old (both inclusive) at the time of consent. 2) Sex: Healthy male and non-pregnant\u002Fnon-lactating females. 3) Subject having normal, dry and sensitive skin. 4) Females of childbearing potential must have a self-reported negative pregnancy test.\n\n  5\\) Subject are generally in good health. 6) Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.\n\n  7\\) If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device\u002Finjection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.\n\n  8\\) Subjects are willing to give written informed consent and are willing to come for regular follow up.\n\n  9\\) Subjects who commit not to use any other skincare products for the entire duration of the study.\n\n  10\\) Subject who has not participated in a similar investigation in the past three months.\n\n  11\\) Willing to use test product throughout the study period.\n\nExclusion Criteria:\n\n* 1\\) History of any dermatological condition of the skin diseases. 2) Subject with present condition of allergic response to any cosmetic product. 3) Subject having allergic response to the ink. 4) Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study.\n\n  5\\) Subjects who have applied topical treatment for at least 4 weeks and any systemic treatment for at least 3 months, before they participated in the study.\n\n  6\\) History of alcohol or drug addiction. 7) Subjects using other marketed products during the study period. 8) Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion.\n\n  9\\) Pregnant or breastfeeding or planning to become pregnant during the study period.\n\n  10\\) History of chronic illness which may influence the cutaneous state. 11) Subjects participating in other similar cosmetics, devices or therapeutic trials or skincare products within the last four weeks.","55 Years",{"count":5,"type":23},[26],"This is a single-center, open-label, split-face, site-randomized validation study, NB250045-NB-V designed to establish and confirm the reliability, reproducibility, and sensitivity of various skin measurement methods. Evaluator blinding will be implemented to minimize observer bias.",[58],"Dry and Sensitive Skin","2026-02-17",{"date":61,"type":38},"2026-02-20",{"date":63,"type":23},"2026-02-27",{"date":65,"type":23},"2026-02-28",{"name":44,"class":45},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":24,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100589946","clinical-study-to-assess-the-safety-efficacy-and-in-use-tolerability-of-herbal-based-sugar-support-effervescent-tablets-in-type-2-diabetes-mellitus-patients-100589946","NCT06961019","Clinical Study to Assess the Safety, Efficacy and In-Use Tolerability of Herbal-Based Sugar Support Effervescent Tablets in Type-2 Diabetes Mellitus Patients","A Proof-of-Science, Single-Treatment, Two-Group, Clinical Evaluation of Safety, In-Use Tolerability, Efficacy of Herbal-Based Sugar Support Effervescent Tablets in Type-2 Diabetes Mellitus (T2DM) Patients","Inclusion Criteria:\n\n* 1\\) Male and female individuals with the age between 18 to 65 years at the time of consent.\n\n  2\\) Subject diagnosed with T2DM. 3) Subjects with currently having HbA1c values between 6.5% to 8.0 gm%. 4) Subjects currently managing T2DM by dietary or herbal supplements and exercise only for at least 8 weeks prior to screening for Group 1.\n\n  5\\) Subjects currently managing T2DM by 500 mg Metformin dose for Group 2. 6) Subjects having prescription or diabetes related laboratory reports at the time of screening.\n\n  7\\) Subjects willing to come in fasting state for every study visit. 8) Subjects are willing to give written informed consent and are willing to come for regular follow up.\n\n  9\\) Subjects who commit not to use other medications other than the allocated test treatment for the entire duration of the study.\n\n  10\\) Subjects who have note participated in any other similar clinical study in last 3 months.\n\n  11\\) Willing to use test treatment throughout the study period.\n\nExclusion Criteria:\n\n* 1\\) Subjects diagnosed with other types of Diabetes like T1DM or specific type of DM (i.e., pancreatic injury induced DM, diabetes mellitus caused by Cushing's syndrome or acromegaly, Latent Autoimmune Diabetes in Adults (LADA), Maturing Onset diabetes of the young (MODY) etc.) 2) Subjects with any end organ damage due to diabetes (including microvascular complications like retinopathy, nephropathy and macrovascular complications like ischemic heart disease, peripheral vascular disease and cerebrovascular disease resulting in organ and tissue damage) within 6 months prior to screening.\n\n  3\\) Subjects taking any weight loss medication or dietary supplements, have participated in a weight loss program within 4 weeks prior to screening.\n\n  4\\) Subjects taking any glucose modifying medication like Sulfonylureas, Biguanides (Except 500 mg Metformin), Meglitinides, Thiazolidinediones, DPP-4 inhibitors, GLP-1 agonist, SGLT2 inhibitor, Alpha-glycosidase inhibitors or any other within 8 weeks prior to screening.\n\n  5\\) Subjects having history of drug or alcohol use. 6) Subjects having history of smoking or currently smoking or using any form of smokeless tobacco.\n\n  7\\) Subjects who have deviations in the laboratory reports which could warrant exclusion from the study, as per investigator's opinion.\n\n  8\\) Individuals with uncontrolled hypertension defined as Systolic blood pressure ≥ 140 mm Hg and\u002For Diastolic blood pressure ≥ 90 mm Hg with or without anti-hypertensives.\n\n  9\\) Subjects who are hypersensitive to any of the components of the treatment. 10) Subjects who have planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.\n\n  11\\) Participation in a study of any other treatment within 90 days prior to the screening.\n\n  12\\) Pregnant or breastfeeding or planning to become pregnant during the study period.","65 Years",{"count":76,"type":23},14,[26],"This is a Proof-of-Science, exploratory, prospective, single-treatment, two-group, clinical safety, efficacy and tolerability study of herbal based Sugar support effervescent tablets on the patients with Type 2 Diabetes Mellitus.",[80],"Type2 Diabetes Mellitus","RECRUITING","2026-02-03",{"date":84,"type":38},"2026-02-05",{"date":86,"type":38},"2025-08-25",{"date":88,"type":23},"2026-03-14",{"name":44,"class":45},1,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":74,"enrollmentInfo":97,"targetDuration":4,"studyType":24,"phases":99,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100618567","exploratory-clinical-investigation-on-neurosensory-responses-via-eeg-headband-in-adults-with-mild-to-moderate-atopic-dermatitis-after-application-of-marketed-product-compared-with-placebo-water-application-100618567","NCT07333300","Exploratory Clinical Investigation on Neurosensory Responses Via EEG Headband in Adults With Mild to Moderate Atopic Dermatitis After Application of Marketed Product Compared With Placebo (Water Application).","Inclusion Criteria:\n\n* Age: 18 to 65 years (both inclusive) at the time of consent having mild to moderate atopic dermatitis. 2. Sex: Healthy male and non-pregnant\u002Fnon-lactating females. 3. Females of childbearing potential must have a self-reported negative pregnancy test. 4. Subject are generally in good health. 5. Subjects who agree to come to the facility with clean and dry scalp and hair 6. Subjects with mild to moderate Atopic Dermatitis determined by Eczema\n\nArea and Severity Index (EASI) score with moderate erythema (redness:\n\nscore 2) and mild scratch mark (scratching: score 1) will be enrolled into the study 7. Subjects are not allowed to participate in any other study until this study is complete. 8. Subjects willing and able to follow the study directions. 9. Having childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device\u002F injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam,partner vasectomy or abstinence). Females will be considered as nonchildbearing potential if they are surgically sterile, have been postmenopausal for at least 1 year or have had a tubal ligation. 10. Subjects willing to give written consent through subject information sheet. 11. Subjects have not participated in a similar investigation in the past three months. 12. Subjects willing to use test product throughout the study period.\n\nExclusion Criteria:\n\n* History of any dermatological condition of the skin diseases. 2. Subject with present condition of allergic response to any cosmetic product. 3. Subjects with other dermatologic diseases besides AD whose presence or treatments could interfere with the assessment of disease (eg, Psoriasis). 4. Subjects who used systemic immunosuppressants within 4 weeks, topical steroids or immunomodulators within 1 week, moisturizers within 12 hours before evaluation. 5. History of alcohol or drug addiction. 6. The subject has a known allergy or sensitivity to soaps, lotions, detergents, detanglers or fragrances. 7. The subject has any other skin conditions i.e. cuts, scratches, ring worms, etc. which in the opinion of the Investigator, will interfere with the study results or will create undue risk for the subject. 8. Subjects having diabetes, hepatitis, epilepsy, thyroid or have or had any kind of cancer. 9. The subject must not have participated in a clinical study within 4 weeks prior to the screening visit of this study. 10. Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion. 11. Pregnant or breastfeeding or planning to become pregnant during the study period. 12. History of chronic illness which may influence the cutaneous state.",{"count":98,"type":23},20,[26],"This is a prospective, exploratory, double-blind, single-visit internal validation study designed to evaluate neurosensory responses using electroencephalography head band (EEG) in adult subjects with mild to moderate atopic dermatitis (AD) following a single topical application of marketed product compared with placebo (water application).",[102],"Atopic Dermatitis (AD)",[104],"atopic dermatitis","2025-12-30",{"date":107,"type":38},"2026-01-12",{"date":109,"type":23},"2026-01-04",{"date":111,"type":23},"2026-01-06",{"name":44,"class":45},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":17,"sex":18,"minAge":121,"maxAge":53,"enrollmentInfo":122,"targetDuration":4,"studyType":24,"phases":124,"briefSummary":125,"conditions":126,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100617910","clinical-study-to-assess-safety-effectiveness-and-in-use-tolerability-of-saffron-extract-capsules-for-improving-skin-health-and-reducing-signs-of-aging-on-healthy-adult-male-and-female-subjects-100617910","NCT07324759","Clinical Study to Assess Safety, Effectiveness and In-Use Tolerability of Saffron Extract Capsules for Improving Skin Health and Reducing Signs of Aging on Healthy Adult Male and Female Subjects.","Effect of Saffron Extract Capsule Supplement on Skin Rejuvenation and Anti-Ageing in Healthy Adult Male and Female Subjects: Randomised, Double-Blind, Two-Group, Prospective, Multi-Centre Exploratory Study","GLOW","Inclusion Criteria:\n\n1. Age: 30 to 55 years (both inclusive) at the time of consent.\n2. Sex: Adult male and female having wrinkles and fine lines at crow feet's area, facial hyperpigmentation and dark spots such as tan, pimple marks, sunspots, age spots, uneven skin tone on both side of face.\n3. Females of childbearing potential should have a self-reported negative urine pregnancy test at the time of screening visit.\n4. Subjects should not have used any cosmetic, nutraceutical or therapeutic products for skin ageing in last 1 month.\n5. Subjects must be willing to stop using any cosmetics or any medical products for skin ageing for the duration of the study.\n6. Subjects are not allowed to participate in any other study until this study is complete.\n7. Subjects must be willing and able to follow the study directions and to return for all specified visits with the product.\n8. Subjects must agree to record each use of the test products in the subject's diary card on daily basis.\n9. Subjects must agree to record medication use during the study.\n\nExclusion Criteria:\n\n1. Subjects who are on steroids for last six months and using immunosuppressive, anti-inflammatory, or hormone-modulating medications that may interfere with study outcomes.\n2. Subjects who have used any cosmetic, nutraceutical or therapeutic products for skin last one months.\n3. Subjects currently using any oral supplement and topical products containing kojic acid, glycolic acid, niacinamide, alpha arbutin, vitamin C, retinoids, peptides, exfoliating acids, or any other skin-lightening, anti-ageing, or depigmenting agents within the past 4 weeks.\n4. Subjects with a known history of hypersensitivity, allergic reactions, or intolerance (such as drowsiness, stomach discomfort, nausea, or vomiting).\n5. Subjects with other dermatologic diseases whose presence or products could interfere with the assessment of study.\n6. Subjects that are pregnant and\u002For breastfeeding.\n7. The subject has a known allergy or sensitivity to product ingredients.\n8. Subjects if do not agree to limit sun exposure to affected areas such as face during prolonged sun exposure.\n9. The subject has any other skin conditions i.e. cuts, scratches, ring worms, etc. which in the opinion of the Investigator, will interfere with the study results or will create undue risk for the subject.\n10. The subject has any of the conditions or factors that the Investigator believes may affect the response of the skin or the interpretation of the test results.\n11. The subject is currently taking or has taken any medication, which the Investigator believes may influence the interpretation of the data.\n12. Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion.","30 Years",{"count":123,"type":23},50,[26],"This is a randomized, double-blind, comparative, two-arm, prospective, interventional, multi-centre clinical study to evaluate the safety, efficacy, and in-use tolerability of test products, standardized saffron extract capsules, on skin rejuvenation and age-defying benefits in healthy adult male and female subjects.",[127,128,129,130],"Wrinkles","Fine Lines","Hyperpigmentation","Dark Spots","2025-12-24",{"date":133,"type":38},"2026-01-07",{"date":135,"type":23},"2026-01-01",{"date":137,"type":23},"2026-05-30",{"name":44,"class":45},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":74,"enrollmentInfo":146,"targetDuration":4,"studyType":24,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":4},"100608699","clinical-safety-and-efficacy-study-of-water-flosser-in-enhancing-oral-health-among-healthy-adults-having-plaque-induced-gingivitis-and-dental-plaque-accumulation-100608699","NCT07204951","Clinical Safety and Efficacy Study of Water Flosser in Enhancing Oral Health Among Healthy Adults Having Plaque-induced Gingivitis and Dental Plaque Accumulation","A Double-Blind, Randomized, Control-Arm Clinical Study to Evaluate the Safety and Efficacy of Test Water Flosser in Enhancing Oral Health Among Healthy Adults Having Plaque-Induced Gingivitis and Dental Plaque Accumulation","Inclusion Criteria:\n\n1. Age: 18 to 65 years (both inclusive) old at the time of consent.\n2. Sex: Healthy adult males and non-pregnant\u002Fnon-lactating females.\n3. Females of childbearing potential have a self-reported negative urine pregnancy test at the time of the screening visit and agree to follow an accepted method of birth control for the duration of the study such as condoms, foams, jellies, diaphragm, intrauterine device etc.\n4. Subjects are generally in good general health as determined from recent medical history.\n5. Subjects with mild to moderate gingivitis and good oral health, without hard or soft tissue lesions, with moderate gingivitis characterized by more than 30% bleeding sites and probing depths of ≤3 mm without attachment loss.\n6. Anterior teeth without restorations.\n7. No dental treatments being performed before or during the study period.\n8. Possessing at least 20 permanent teeth (excluding the third molars) and 5 evaluable teeth in each quadrant.\n9. Subjects who agree to discontinue the use of over-the-counter any teeth products throughout the trial except for the ADA-approved toothbrush and toothpaste provided during the study.\n10. Subjects who agree to refrain from the use of any other type of floss or similar dental product during the study.\n11. Agree not to participate in any other oral\u002Fdental product studies during the trial.\n12. Agree to return for all scheduled visits and follow study procedures.\n13. Subjects who are willing to complete all study procedures including study-related questionnaires and comply with study requirements.\n\nExclusion Criteria:\n\n1. Subjects who are undergoing treatment for gingivitis, caries, dental plaque and sensitivity.\n2. Subjects are present with fixed orthodontic appliances on the facial surfaces of the maxillary arch.\n3. Subjects have dental crowns, veneers or composite restorations on gradable maxillary anterior teeth (canine to canine) or mandibular anterior teeth.\n4. Subjects have any oral pathologies or gross neglect of home care requiring prompt treatment, including periodontal disease, as evidenced by purulent exudate, tooth mobility, and\u002For other signs indicating that the integrity of the data collected for that subject might be compromised.\n5. Subjects are present with any pre-existing oral or medical condition that the Investigator\u002Fdesignee determines may place the subject at increased health risk from study participation.\n6. Suffering from untreated dental caries, mucosal lesions, oral tumors or severe systemic diseases that may affect periodontal diseases.\n7. Subjects have any known allergies to over-the-counter oral hygiene\u002Fproducts.\n8. Subjects have any known allergies to the trial product ingredients.\n9. The subject must have participated in a clinical study with oral care or oral hygiene within 4 weeks before the screening visit of this study.\n10. Any other condition which could warrant exclusion from the study, as per the Investigator's discretion\n11. Subjects who smoke and are pan eaters.\n12. Subjects with hypersensitive teeth.\n13. Subjects having chipped teeth and defective restorations.\n14. Subjects having deep periodontal pockets.\n15. Subjects having bridgework in their teeth and dentures which interrupt during evaluation.\n16. Subjects undergoing treatment with antibiotics, anti-inflammatory, anticonvulsants, anti-histaminic, anti-depressant, anti-histaminic, sedatives, tranquilizers or daily analgesic drugs.\n17. Subjects having uncontrolled metabolic disease.\n18. Subjects' overexposure to acidic by dietary and environment exposure.",{"count":147,"type":23},64,[26],"This is a double-blind, randomized, control-arm clinical study to evaluate safety and efficacy of test water flosser in enhancing oral health among healthy adults having plaque-induced gingivitis and dental plaque accumulation.",[151],"Plaque Induced Gingivitis","2025-11-06",{"date":154,"type":38},"2025-11-10",{"date":156,"type":23},"2025-11-13",{"date":158,"type":23},"2025-12-06",{"name":44,"class":45},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":74,"enrollmentInfo":167,"targetDuration":4,"studyType":24,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100607999","dermatological-safety-and-skin-compatibility-evaluation-of-test-products-100607999","NCT07195851","Dermatological Safety and Skin Compatibility Evaluation of Test Products","Dermatological Safety and Skin Compatibility Evaluation of Test Product Following Cosmetics Europe: Product Test Guidelines for Assessment of Human Skin Compatibility (Colipa Standard, 1997)","Inclusion Criteria:\n\n1. Age: 18-65 years (both inclusive) at the time of consent.\n2. Sex: Males and non-pregnant\u002Fnon-lactating females (preferably equal number of males and females).\n3. Subject with normal Fitzpatrick skin type III to VI (Human skin colour determination scale).\n4. Females of childbearing potential must have a self-reported negative pregnancy test.\n5. Subject who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results.\n6. Subject is in good general health as determined by the Investigator on the basis of medical history.\n7. Subjects is willing to maintain the test patches in designated positions for 24 Hours.\n8. Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.\n9. Subject must be able to understand and provide written informed consent to participate in the study.\n10. Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given.\n11. For Sensitive Specific Skin Study Only:\n\n    * Subject scoring greater than 30 for Section 2 - Sensitive v\u002Fs Resistant skin in modified Dr Baumann's skin type questionnaire.\n    * Subject with sensitive skin as confirmed by Lactic Acid stinging test.\n\nExclusion Criteria:\n\n1. Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.\n2. Medication which may affect skin response and\u002For past medical history.\n3. Subject having history of diabetes\n4. Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.\n5. Subject suffering from any active clinically significant skin diseases which may contraindicate.\n6. Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer.\n7. Participation in any patch test for irritation or sensitization within the last four weeks.\n8. Subject having history of asthma or COPD (Chronic obstructive pulmonary disease).\n9. Use of any:\n\n   i. Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application. ii. Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. iii. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and\u002For eye drops are permitted)\n10. Topical drugs used at application site.\n11. Subject with Self-reported Immunological disorders such as HIV positive, AIDS and\u002For systemic lupus erythematous.\n12. Individual who has a medical condition or is taking or has taken a medication which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.\n13. Subject with known allergy or sensitization to medical adhesives, bandages.\n14. Participation in other patch study simultaneously.",{"count":168,"type":23},26,[26],"Dermatological Safety and Skin Compatibility Evaluation of Test Product following Cosmetics Europe: Product Test Guidelines for Assessment of Human Skin Compatibility (Colipa Standard, 1997)",[172],"Healthy Subjects","2025-09-24",{"date":175,"type":38},"2025-09-29",{"date":177,"type":23},"2025-09",{"date":179,"type":23},"2025-10",{"name":44,"class":45},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":74,"enrollmentInfo":188,"targetDuration":4,"studyType":24,"phases":189,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":198,"leadSponsor":199,"locationsCount":4},"100601358","to-assess-skin-safety-of-test-products-by-patch-test-on-adult-healthy-human-subjects-100601358","NCT07109453","To Assess Skin Safety of Test Product(s) by Patch Test on Adult Healthy Human Subjects","Dermatological Safety Assessment of Test Products Using Primary Irritation Patch Test (PIPT) in Healthy Adult Human Subjects","Inclusion Criteria\n\n* Age: 18-65 years (both inclusive) at the time of consent.\n* Sex: Males and non-pregnant\u002Fnon-lactating females (preferably equal number of males and females).\n* Subject with normal Fitzpatrick skin type III to V (Human skin colour determination scale).\n* Females of childbearing potential must have a self-reported negative pregnancy test.\n* Subject who do not have any previous\n* history of adverse skin conditions and are not under any medication likely to interfere with the results.\n* Subject is in good general health as determined by\n* the Investigator on the basis of medical history.\n* Subjects is willing to maintain the test patches in designated positions for 24 Hours.\n* Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.\n* Subject must be able to understand and provide written informed consent to participate in the study.\n* Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given.\n* For Sensitive Skin Condition Only:\n* Subject scoring greater than 30 for Section 2 - Sensitive v\u002Fs Resistant skin in modified Dr Baumann's\\* skin type questionnaire.\n* Subject with sensitive skin as confirmed by Lactic Acid Stinging Test.\n\nExclusion Criteria:\n\n* Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.\n* Medication which may affect skin response and\u002For past medical history.\n* Subject having history of diabetes\n* Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.\n* Subject suffering from any active clinically significant skin diseases which may contraindicate.\n* Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer.\n* Participation in any patch test for irritation or sensitization within the last four weeks.\n* Subject having history of asthma or COPD (Chronic obstructive pulmonary disease).\n* Use of any:\n* Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application.\n* Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. iii. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and\u002For eye drops are permitted)\n* Topical drugs used at application site.\n* Subject with Self-reported Immunological disorders such as HIV positive, AIDS and\u002For systemic lupus erythematous.\n* Individual who has a medical condition or is taking or has taken a medication which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.\n* Subject with known allergy or sensitization to medical adhesives, bandages.\n* Participation in other patch study simultaneously",{"count":168,"type":23},[26],"To Check Dermatological Safety of Test Products by 24 Hours Patch Testing",[192,193],"Normal","Sensitive Skin","2025-08-07",{"date":196,"type":38},"2025-08-08",{"date":86,"type":23},{"date":177,"type":23},{"name":44,"class":45},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":186,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":74,"enrollmentInfo":206,"targetDuration":4,"studyType":24,"phases":207,"briefSummary":190,"conditions":208,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":210,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":214,"locationsCount":4},"100597950","to-assess-skin-safety-of-test-products-by-patch-test-on-adult-healthy-human-subjects-100597950","NCT07065149","To Assess Skin Safety of Test Product(s) by Patch Test on Adult Healthy Human Subjects.","Inclusion Criteria:\n\n1\\) Age: 18-65 years (both inclusive) at the time of consent. 2) Sex: Males and non-pregnant\u002Fnon-lactating females (preferably equal number of males and females). 3) Subject with normal Fitzpatrick skin type III to V (Human skin colour determination scale). 4) Females of childbearing potential must have a self-reported negative pregnancy test. 5) Subject who do not have any previous history of adverse skin conditions and are not under any medication likely to interfere with the results. 6) Subject is in good general health as determined by the Investigator on the basis of medical history. 7) Subjects is willing to maintain the test patches in designated positions for 24 Hours. 8) Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits. 9) Subject must be able to understand and provide written informed consent to participate in the study. 10) Subject is willing to refrain from vigorous physical exercise during the study period and follow all the instruction given. 11) For Sensitive Skin Condition Only:\n\n* Subject scoring greater than 30 for Section 2 - Sensitive v\u002Fs Resistant skin in modified Dr Baumann's\\* skin type questionnaire.\n* Subject with sensitive skin as confirmed by Lactic Acid Stinging Test.\n\nExclusion Criteria:\n\n1. Subject having skin irritation, blemishes, excessive hair, moles, pigmentation, pimples, marks (e.g. tattoos (within the previous 3 months), scars, sunburn), open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the test site(s) i.e. back that can interfere with the reading.\n2. Medication which may affect skin response and\u002For past medical history. 3) Subject having history of diabetes 4) Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.\n\n5\\) Subject suffering from any active clinically significant skin diseases which may contraindicate. 6) Subject having history of any skin diseases including eczema, atopic dermatitis or active cancer. 7) Participation in any patch test for irritation or sensitization within the last four weeks. 8) Subject having history of asthma or COPD (Chronic obstructive pulmonary disease). 9) Use of any: i. Prescribed or over-the-counter (OTC) anti-inflammatory drug within five (5) days prior to application. ii. Antihistamine medication or immunosuppressive drugs within seven (7) days prior to first patch application. iii. Systemic or topical corticosteroids at patch site within four (4) weeks of test product application (steroidal nose drops and\u002For eye drops are permitted) 10) Topical drugs used at application site. 11) Subject with Self-reported Immunological disorders such as HIV positive, AIDS and\u002For systemic lupus erythematous. 12) Individual who has a medical condition or is taking or has taken a medication which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk. 13) Subject with known allergy or sensitization to medical adhesives, bandages. 14) Participation in other patch study simultaneously.",{"count":168,"type":23},[26],[209],"Normal Skin",{"date":196,"type":38},{"date":212,"type":23},"2025-08",{"date":177,"type":23},{"name":44,"class":45},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":74,"enrollmentInfo":222,"targetDuration":4,"studyType":24,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":4},"100600525","clinical-study-to-assess-the-safety-and-efficacy-of-acv-moringa-effervescent-tablet-intake-on-weight-management-in-overweight-and-class-i-obese-study-participants-100600525","NCT07098624","Clinical Study to Assess the Safety and Efficacy of ACV Moringa Effervescent Tablet Intake on Weight Management in Overweight and Class I Obese Study Participants","A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Centre, Clinical Study to Evaluate the Safety and Efficacy of Intake of ACV Moringa on the Degree of Weight Change in Overweight and Class I Obese Study Participants.","Inclusion Criteria:\n\n1. Age: 18- 65 years (both inclusive) at the time of consent.\n2. Sex: Males and non-pregnant\u002Fnon-lactating females (preferably equal number of males and females).\n3. Females of childbearing potential must have a self-reported negative urine pregnancy.\n4. Female of childbearing potential must have a reported negative pregnancy during screening and the end of the study\n5. Subject is in good general health as determined by the Investigator on the basis of medical history.\n6. Subjects who are classified as overweight (BMI 25.0-29.9 kg\u002Fm²) or as having Class I obesity (BMI 30.0-34.9 kg\u002Fm²).\n7. Subjects with a total body fat percentage exceeding 25% for men and 30% for women using Bioimpedance test.\n8. Subject is willing to forgo liposuction procedures or any weight loss therapy 3 months prior to and for the duration of the study.\n9. Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.\n10. If the female subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device\u002Finjection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.\n11. If currently using hormonal contraception, has been using this form of contraception for at least 6 months and agrees to continue using the same contraception for the duration of the study.\n12. Subject who agree to consume a vegetarian\u002Fnon-vegetarian diet of approximately 2000 kcal\u002Fday (14% protein, 25%Fat and 61% carbohydrate).\n13. Subjects willing to follow the given diet and maintain their physical activity by a Diet and physical activity diary.\n14. Subjects must possess an Android smartphone to facilitate daily app login and study-related activities.\n15. Subjects are willing to give written informed consent and are willing to follow the study procedure.\n16. Subjects who commit not to use any other medication for weight management other than the test treatment for the entire duration of the study.\n17. Willing to use test treatment throughout the study period.\n18. Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.\n\nExclusion Criteria:\n\n1. Subjects BMI is between less than 25 and greater than 35 kg\u002Fm2.\n2. Subjects having past or present history or clinically significant findings indicating cardiovascular disease, type 2 diabetes mellitus, hypertension, endocrine, pulmonary, neurological or psychological disorders, hypo or hyperthyroidism and renal disorders.\n3. Subjects with a history of gastrointestinal disorders, including chronic gastritis, gastric discomfort, or any diagnosed gastrointestinal conditions.\n4. Subjects having drug and alcohol abuse.\n5. Smokers and tobacco users.\n6. Subjects having more than 5 kg variation in body weight within 3 months before study entry.\n7. Subjects using other weight loss medications, as well as stimulants, laxatives or diuretics taken solely for the purpose of weight loss.\n8. Undergone surgery before 30 days of screening or planning to undergo surgery within the study period.\n9. Subjects having chronic diarrhoeal disorders, cancer, hepatic dysfunction, and human immunodeficiency virus (HIV) infection.\n10. Participation in other drugs, investigational medicinal product, any herbal products and\u002For cosmetics intended to weight loss clinical trials within 3 months before enrolment in this trial.\n11. Any other diseases\u002Fco-morbidity that is considered by the Investigator as an exclusion.\n12. With severe hepatic and\u002For renal impairment, liver enzyme level (ALT and\u002For AST) is greater than 2.5 times the upper normal limit.\n13. Taking antibiotic therapy, anti-depressant treatment or treatment related to anxiety in the month preceding the study,\n14. Taking anti-depressant treatment or treatment related to anxiety Subject in a state of depression.\n15. Non-stable weight during the last 6 months (\\>5% change in total weight)\n16. Consuming food supplements or functional foods known to have an influence on weight management in the month preceding the inclusion and\u002For likely to take during the test\n17. Following or having followed a hypocaloric diet (energy intake \\\u003C1,500 kCal\u002Fday) in the month preceding inclusion and\u002For likely to undertake this diet during the test.\n18. Diagnosed eating disorders (bulimia, anorexia nervosa, vomiting),\n19. Using topical anti-cellulite treatments.\n20. Pregnant or breastfeeding or planning to become pregnant during the study period.\n21. Subject has a history of chronic illness which may influence the cutaneous state.\n22. Subjects participating in other similar nutraceuticals, food, supplemental or therapeutic trials within the last four weeks.\n23. Any other condition which could warrant exclusion from the study, as per the Investigator's discretion.",{"count":223,"type":23},66,[26],"A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Centre, Clinical Study to Evaluate the Safety and Efficacy of Intake of ACV Moringa on the Degree of Weight Change in Overweight and Class I Obese Study Participants",[227],"Obese or Overweight Healthy Volunteers","2025-07-31",{"date":230,"type":38},"2025-08-01",{"date":232,"type":23},"2025-07-24",{"date":234,"type":23},"2025-11-04",{"name":44,"class":45},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":24,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":256,"locationsCount":4},"100568936","a-clinical-study-to-determine-the-safety-and-efficacy-of-an-oral-probiotic-supplementation-in-the-management-of-irritable-bowel-syndrome-with-protein-digestion-100568936","NCT06687720","A Clinical Study to Determine the Safety and Efficacy of An Oral Probiotic Supplementation in the Management of Irritable Bowel Syndrome With Protein Digestion.","A Preliminary Investigation of the Safety and Effectiveness of Oral Probiotics Supplementation for Management of Irritable Bowel Syndrome: A Randomized, Open Label, Placebo-Arm, Comparative, Interventional, Proof-of-Science Study","Inclusion Criteria:\n\n1. The subject is an adult male or female aged between 18 to 60 years old.\n2. Clinically diagnosed with irritable bowel syndrome (IBS) based on Rome IV criteria: Abdominal pain at least 4 days per month - over at least 2 months - associated with one or more of the following:\n\n   i. Related to defecation ii. A change in frequency of stool iii. A change in form (appearance) of stool iv. After appropriate evaluation, the symptoms cannot be fully explained by another medical condition\n3. The subject is having refrigerator at their home for storage of test treatment.\n4. The subject is willing to provide written informed consent, comply with the study procedures, and be present for all the visits.\n5. The subject is willing to abstain from using any other treatments for irritable bowel syndrome during the study period, unless for a medical urgency.\n6. The subject is in a stable medical condition, not requiring immediate intervention or hospitalization.\n7. If the subject is female, she is willing to use a highly effective method of contraception throughout the clinical investigation.\n\n   i. Females of childbearing potential must practice and maintain an established method of birth control (e.g., IUD, hormonal implant device\u002Finjection, birth control pills, diaphragm, condoms with spermicide, partner vasectomy, or abstinence).\n\nii. Non-childbearing potential females who are surgically sterile, post-menopausal for at least 1 year, or have had a tubal ligation, must have been using hormonal contraception for at least 6 months and agree to continue using the same contraception for the study duration.\n\nExclusion Criteria:\n\n1. The subject has a history of diagnosis of either hypertension, diabetes, or liver disease.\n2. The subject has any other significant medical condition that could interfere with the study or pose a risk to the participant.\n3. The subject has used medications that could influence the study outcomes, such as antibiotics, immunosuppressive drugs, and probiotics or prebiotics supplements within the last 4 weeks.\n4. The subject works in frequent night shifts (working night shifts at least 3 times per week), and refuses to change the lifestyle.\n5. The subject has a history of alcohol abuse.\n6. The subject is either pregnant, lactating, or plans on conceiving during the course of the study.\n7. The subject has participated in other clinical studies or received any investigational agent in the previous 30 days.\n8. The subject has other significant gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis, celiac disease).\n9. The subject has any condition that, in the investigator's judgment, would compromise the subject's safety or study integrity.\n10. The subject has abnormal baseline Haemoglobin (Hb), Complete Blood Count (CBC), Urine Routine\u002FMicroscopy (R\u002FM), or Stool Routine\u002FMicroscopy (R\u002FM) results that suggest a different pathology than irritable bowel syndrome.","60 Years",{"count":245,"type":23},18,[26],"This is an open-label, two-arm, prospective, interventional, in-use safety and efficacy study of an oral probiotic supplementation in adult subjects having irritable bowel syndrome.",[249],"Irritable Bowel Syndrome","2024-11-12",{"date":252,"type":38},"2024-11-14",{"date":254,"type":23},"2024-11-30",{"date":254,"type":23},{"name":44,"class":45},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":17,"sex":18,"minAge":264,"maxAge":74,"enrollmentInfo":265,"targetDuration":4,"studyType":24,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":4},"100568921","a-clinical-study-to-assess-the-safety-and-effectiveness-of-test-products-in-mild-to-moderate-atopic-dermatitis-ad-patients-100568921","NCT06687512","A Clinical Study to Assess the Safety and Effectiveness of Test Products in Mild to Moderate Atopic Dermatitis (AD) Patients.","An Exploratory, Proof-of-Concept, Double-Blind, Placebo-Controlled, Randomized, Comparative, Interventional, Prospective, Safety In-Use Tolerability and Efficacy Study of Test Products in Patients With Mild to Moderate Atopic Dermatitis (AD).","Inclusion Criteria:\n\n* 1\\) Age: For children: 6 years and above (both inclusive) at the time of parental consent\u002Fassent and For Adults: 18 to 65 years (both inclusive) at the time of consent.\n\n  2\\) Sex: Healthy children (male or female) and adults (males and non-pregnant\u002Fnon-lactating females) with mild to moderate atopic dermatitis.\n\n  3\\) Subject's with TEWL \\>15% and Moisture level \\\u003C20% at the time of screening. 4) Subject's with mild to moderate Atopic Dermatitis determined by Eczema Area and Severity Index (EASI) score with moderate erythema (redness: score 2) and mild scratch mark (scratching: score 1) will be enrolled into the study.\n\n  5\\) Subject is diagnosed with mild to moderate atopic dermatitis with at least 1 active lesion that are accessible for instrumental measurements.\n\n  6\\) Females of childbearing potential should have a negative urine pregnancy test at the time of screening visit.\n\n  7\\) Subjects (adults and children) are generally in good general health as determined from a recent medical history, except for the atopic dermatitis.\n\n  8\\) If subjects (adults and children) are using or taking any prescription or over the counter (OTC) medications prescribed by their physicians, they must be taking the medication for at least 4 weeks.\n\n  9\\) Subject's and child's legal parent or guardian must agree to use the same brands and agree not to switch brands or variants of any skin care products during the study period.\n\n  10\\) Subject's and child's legal parent or guardian must agree to limit the sun exposure to affected areas such as arms, legs covered during prolonged sun exposure.\n\n  11\\) Subject's and child's legal parent or guardian must agree to dress the subjects in loose clothing to allow easy exposure to the entire body during study visits and throughout study duration of 60 days.\n\n  12\\) Subjects and Legal parent or guardian must avoid allowing the subject a hot or cold beverage within one hour of their scheduled visits and for the duration of all clinic visits, warm beverages are allowed.\n\n  13\\) Subjects and Legal parent or guardian must avoid allowing subject to swim or play in chlorinated water during study period.\n\n  14\\) Subjects are not allowed to participate in any other study until this study is complete.\n\n  15\\) Subjects and child's legal parent or guardian must be willing and able to follow the study directions and to return for all specified visits with the subject.\n\n  16\\) Subjects and Child's legal parent or guardian must be willing to stop using all of the subject's normal body lotions for the duration of the study (8 weeks) and to use the provided test daily lotion as directed.\n\n  17\\) Subjects and Child's legal parent or guardian must agree to record each use of the test products in the subject's diary card on daily basis.\n\n  18\\) Subjects and Child's legal parent or guardian must agree to record medication use during the study.\n\n  19\\) Subject's and child's legal parent or guardian must read, sign, and receive a copy of Informed Consent\u002FParental Informed Consent prior to initiate of study procedures.\n\n  20\\) Having childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device\u002Finjection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.\n\n  21\\) Subjects willing to give written informed consent and are willing to come for regular follow up.\n\n  22\\) Subjects have not participated in a similar investigation in the past three months.\n\n  23\\) Subjects willing to use test product throughout the study period.\n\nExclusion Criteria:\n\n* 1)Subjects with AD on the scalp (with hair), palms, and soles. 2) Subjects with active skin infections. 3) Subjects with other dermatologic diseases besides AD whose presence or treatments could interfere with the assessment of disease (eg, Psoriasis).\n\n  4\\) Subjects who used systemic immunosuppressants within 4 weeks, topical steroids or immunomodulators within 1 week, moisturizers within 12 hours before evaluation.\n\n  5\\) Subjects with milk allergies. 6) Change in current prescriptions (within 4 weeks of screening) or new and\u002For additional prescriptions for the skin condition (within 4 weeks of screening) or during the study.\n\n  7\\) The subject has a known allergy or sensitivity to soaps, lotions, detergents, detanglers or fragrances.\n\n  8\\) The subject has any other skin conditions i.e. cuts, scratches, ring worms, etc. which in the opinion of the Investigator, will interfere with the study results or will create undue risk for the subject.\n\n  9\\) The subject has any of the conditions or factors that the Investigator believes may affect the response of the skin or the interpretation of the test results.\n\n  10\\) Subjects having diabetes, hepatitis, epilepsy, thyroid or have or had any kind of cancer.\n\n  11\\) The subject is currently taking or has taken any medication, which the Investigator believes may influence the interpretation of the data, such as 3 or more dosage or 3 or more days of anti-inflammatories (within 1 week of study enrolment) or anti-histamines and steroids.\n\n  12\\) The subject must not have participated in a clinical study within 4 weeks prior to the screening visit of this study.\n\n  13\\) Any other condition which could warrant exclusion from the study, as per the dermatologist's\u002Finvestigator's discretion.\n\n  14\\) Pregnant or breastfeeding or planning to become pregnant during the study period.\n\n  15\\) History of chronic illness which may influence the cutaneous state.","6 Years",{"count":266,"type":23},44,[26],"This is an exploratory, proof-of-concept, double-blind, placebo-controlled, randomized, comparative, interventional, prospective, safety in-use tolerability and efficacy study of test products in patients with mild to moderate Atopic Dermatitis.",[270],"Atopic Dermatitis",{"date":272,"type":38},"2024-11-13",{"date":274,"type":23},"2024-11-20",{"date":276,"type":23},"2025-02-20",{"name":44,"class":45},{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":53,"enrollmentInfo":285,"targetDuration":4,"studyType":24,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":4},"100558509","proof-of-science-prospective-interventional-three-arm-double-blind-randomized-safety-and-efficacy-real-world-evidence-study-100558509","NCT06552039","Proof-of-Science, Prospective, Interventional, Three-arm, Double-Blind, Randomized, Safety and Efficacy Real World Evidence Study.","Scientific Evaluation of the Safety and Efficacy of Herbal and Non Herbal Formulations in Mitigating Hair Fall, Promoting Hair Growth, and Preventing Premature Hair Graying.","Inclusion Criteria:\n\n1. Age: 18 to 55 years and above (both inclusive) at the time of consent.\n2. Sex: Males and non-pregnant\u002Fnon-lactating females (preferably equal number of males and females).\n3. Females of childbearing potential must have a self-reported negative urine pregnancy.\n4. Subject is in good general health as determined by the Investigator on the basis of medical history.\n5. Female with 40-50 counts and male with 25 -30 counts of hair fall at screening.\n6. Subject having AGA and premature Gray hair at a time of screening.\n7. Subject having premature gray hair at a time of screening.\n8. Subject with pro-claimed nonpathological thinning of hair.\n9. Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.\n10. If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device\u002Finjection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will beconsidered as non-childbearing potential if they are surgically sterile, have been post menopausal for at least 1 year or have had a tubal ligation.\n11. Subjects are willing to give written informed consent and are willing to follow the study procedure.\n12. Subjects who commit not to use any other medicated\u002F prescription shampoos\u002Fhair care products (containing Minoxidil), any other hair growth products or hair colour or dye, other than the test products for the entire duration of the study.\n13. Willing to use test products throughout the study period.\n14. Subject is willing and able to follow and allow study staff to performed study test methods.\n15. Subject is willing and able to follow the study directions, to participate in the study, returning for all specified visits.\n16. Subject must be able to understand and provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Subject have history of severe hair fall due to any clinically significant problems like anaemia, thyroid problems.\n2. Subject have history of any dermatological condition of the scalp other than hair loss and dandruff.\n3. Subject have history of any prior hair growth procedures (e.g. hair transplant or laser).\n4. Subject who had taken topical treatment of hair loss for at least 4 weeks.\n5. Subject who had taken any systemic treatment for at least 3 months.\n6. History of alcohol or drug addiction.\n7. Subject having history or resent condition of irritated or visibly inflamed scalp or severe scalp disease.\n8. Subject having history or present condition of an allergic response to any cosmetic products, any other condition which could warrant exclusion from the study.\n9. Pregnant or breast feeding or planning to become pregnant during the study period.\n10. History of chronic illness which may influence the cutaneous state.\n11. Subject have participated any clinical research study related to hair care products.\n12. Subject have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.",{"count":286,"type":23},99,[26],"This is proof-of-science, prospective, interventional, three-arm, double-blind, randomized, safety and efficacy real world evidence study of herbal and non herbal formulations in healthy human subjects having complaint of hair fall and pre-mature graying.",[290],"Hair Fall and Pre-mature Graying","2024-08-11",{"date":293,"type":38},"2024-08-13",{"date":295,"type":23},"2024-08-24",{"date":297,"type":23},"2024-12-24",{"name":44,"class":45},{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":17,"sex":18,"minAge":306,"maxAge":20,"enrollmentInfo":307,"targetDuration":4,"studyType":24,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100558492","a-clinical-study-to-assess-safety-efficacy-and-in-use-tolerability-of-different-dosages-of-hair-growth-products-in-patients-with-mild-to-moderate-androgenic-alopecia-grade-i-to-iii-100558492","NCT06551818","A Clinical Study to Assess Safety, Efficacy and In-use Tolerability of Different Dosages of Hair Growth Products in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III).","Prospective, Interventional, Exploratory, Four-Arm - Dose Response Study, Comparative, Double-Blind, Randomized, Placebo-Control, Proof of Concept, Safety, Efficacy and In-Use Tolerability Study of Three Different Dosage Formulation of Test Hair Growth Products and Placebo in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III).","Inclusion Criteria:\n\n1. Age: 25 to 45 years and above (both inclusive) at the time of consent.\n2. Sex: Males and non-pregnant\u002Fnon-lactating females (preferably equal number of males and females).\n3. Females of childbearing potential must have a self-reported negative urine pregnancy.\n4. Patient is in good general health as determined by the Investigator on the basis of medical history.\n5. Patients having mild to moderate Androgenic Alopecia (Grade I to III) during clinical study and grade will be evaluated by the dermatologist by using Norwood-Hamilton classification and Ludwig pattern scale for female.\n6. Female with 40-50 counts and male with 25 -30 counts of hair fall at screening.\n7. Patient is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.\n8. If the patient is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device\u002Finjection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.\n9. Patients are willing to give written informed consent and are willing to follow the study procedure.\n10. Patients who commit not to use any other medicated\u002F prescription shampoos\u002Fhair care products (containing Minoxidil), any other hair growth products or hair colour or dye, other than the test products for the entire duration of the study.\n11. Willing to consume test products throughout the study period.\n12. Patient is willing and able to follow and allow study staff to performed study test methods.\n13. Patient is willing and able to follow the study directions, to participate in the study, returning for all specified visits.\n14. Patient must be able to understand and provide written informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Patient have history of severe hair fall due to any clinically significant problems like anaemia, thyroid problems.\n2. Patient have history of any dermatological condition of the scalp other than hair loss and dandruff.\n3. Patient have history of any prior hair growth procedures (e.g. hair transplant or laser).\n4. Patient who had taken topical treatment of hair loss for at least 4 weeks.\n5. Patient who had taken any systemic treatment for at least 3 months.\n6. History of alcohol or drug addiction.\n7. Patient having history or resent condition of irritated or visibly inflamed scalp or severe scalp disease.\n8. Patient who is currently participating in or planning on starting weight loss program that may result in a significant change in overall body weight.\n9. Pregnant or breast feeding or planning to become pregnant during the study period.\n10. History of chronic illness which may influence the cutaneous state.\n11. Patient have participated any clinical research study related to hair care products.\n12. Patient have history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.","25 Years",{"count":308,"type":23},72,[26],"This is a prospective, interventional, exploratory, four-arm - dose response study, comparative, double-blind, randomized, placebo-control, proof of concept, safety, efficacy and in-use tolerability study of three different dosage formulation of test hair growth products and placebo in patients with mild to moderate Androgenic Alopecia (Grade I to III).",[312],"Androgenic Alopecia",{"date":293,"type":38},{"date":315,"type":23},"2024-08-30",{"date":317,"type":23},"2025-03-02",{"name":44,"class":45},{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":53,"enrollmentInfo":326,"targetDuration":4,"studyType":24,"phases":327,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":337,"locationsCount":4},"100552775","a-clinical-study-to-determine-the-safety-and-efficacy-of-an-oral-probiotic-supplementation-in-reducing-the-risk-of-kidney-stone-in-adults-with-recurrent-kidney-stone-colic-or-acute-episode-of-colicky-pain-100552775","NCT06477471","A Clinical Study to Determine the Safety and Efficacy of An Oral Probiotic. Supplementation in Reducing the Risk of Kidney Stone in Adults With Recurrent Kidney Stone Colic or Acute Episode of Colicky Pain.","A Preliminary Investigation of the Safety and Effectiveness of Oral Probiotics Supplementation for Reducing the Risk of Kidney Stone in Adults With Recurrent Kidney Stone Colic or Acute Episode of Colicky Pain: An Open-Label, Single-Arm, Prospective, Interventional, Proof-of-Science Study","Inclusion Criteria:\n\n1. The subject is an adult aged between 18 to 55 years old.\n2. The subject has a history of recurrent kidney stone colic or acute episode of colicky pain on clinical examination by Physician.\n3. Subject having refrigerator at their home for storage of test product.\n4. The subject is willing to provide written informed consent and comply with study procedures, including overnight stay for 24 hours at the study centre during both visits.\n5. The subject is willing to abide by the study protocol and restrictions, including abstaining from using any other oral or topical treatments for kidney stone colic during the study period.\n6. The subject is in a stable medical condition, not requiring immediate intervention or hospitalization.\n7. If the subject is female, she is willing to use a highly effective method of contraception throughout the clinical investigation.\n\n   1. Females of childbearing potential must practice and maintain an established method of birth control (e.g., IUD, hormonal implant device\u002Finjection, birth control pills, diaphragm, condoms with spermicide, partner vasectomy, or abstinence).\n   2. Non-childbearing potential females who are surgically sterile, post-menopausal for at least 1 year, or have had a tubal ligation, must have been using hormonal contraception for at least 6 months and agree to continue using the same contraception for the study duration.\n\nExclusion Criteria:\n\n1. The subject has a history of severe renal impairment or chronic kidney disease.\n2. The subject is pregnant\u002Flactating, or is planning on become pregnant during the course of the study.\n3. The subject has presence of significant medical or psychiatric conditions that may interfere with study participation or interpretation of results.\n4. The subject has a history of substance abuse or dependence.\n5. The subject has severe systemic complications of viral infections, cardiovascular disorders, neurological disorders, renal disorders, or autoimmune disorders.\n6. The subject has participated in clinical studies or received any investigational agent in the previous 30 days.\n7. The subject has any condition that, in the investigator's judgment, would compromise the subject's safety or study integrity.",{"count":76,"type":23},[26],"A Preliminary Investigation of the Safety and Effectiveness of Oral Probiotics Supplementation for Reducing the Risk of Kidney Stone in Adults with Recurrent Kidney Stone Colic or Acute Episode of Colicky Pain: An Open-Label, Single-Arm, Prospective, Interventional, Proof-of-Science Study.\n\n14 adults, with recurrent kidney stone colic or acute episode of colicky pain will be enrolled to ensure 12 subjects complete the study",[330],"Recurrent Kidney Stones With Colicky Pain","2024-06-26",{"date":333,"type":38},"2024-06-27",{"date":335,"type":23},"2024-07-30",{"date":293,"type":23},{"name":44,"class":45},""]